Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CompassHER2 RD: T-DM1 and Tucatinib in HER2-Positive Breast Cancer
NCT04457596Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2021
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of tucatinib in breast cancer, sponsored by Cancer and Leukemia Group B. Started Mar 2021; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04457596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457596.